Images List Premium Download Classic

Autoimmune Disorder

Autoimmune Disorder-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
Incyte Holdings Corporation
September 07, 2017 - N°20170253598

The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jaks) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Liquid formulation comprising gm-csf neutralizing compound
Takeda Gmbh
September 07, 2017 - N°20170252436

The present invention relates to aqueous formulations comprising a compound neutralizing gm-csf in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing gm-csf in view of long-term storage. In ...
Compositions and methods for treating b cell mediated autoimmune disorders
Opexa Therapeutics, Inc.
August 31, 2017 - N°20170246272

Provided herein are methods, kits, compositions and uses related to the treatment of a b cell mediated autoimmune disorder with a t cell vaccine comprising a therapeutically effective amount of t cells autologous to the patient and that react to an autoantigen or specific epitope(s) thereof associated with the b cell mediated autoimmune disorder, wherein the treatment is provided ...
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
Incyte Holdings Corporation
August 31, 2017 - N°20170246157

The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase 1 (jak1) and are useful in the treatment of diseases related to the activity of jak1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of ...
Gemoab Monoclonals Gmbh
August 24, 2017 - N°20170240612

The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
Idera Pharmaceuticals, Inc.
August 17, 2017 - N°20170233741

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
Forward Pharma A/s
August 17, 2017 - N°20170231943

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix ...
Controlled release pharmaceutical compositions comprising a fumaric acid ester
Forward Pharma A/s
August 17, 2017 - N°20170231941

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e. G. Psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance ...
N-terminally truncated interleukin-38
Fraunhofer-gesellschaft Zur FÖrdeung Angewandten Forschung E.v.
August 03, 2017 - N°20170218039

The present invention pertains to an n-terminally truncated interleukin (il)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated il-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that il-38 is n-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune ...
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and ...
Pimco 2664 Limited
August 03, 2017 - N°20170217881

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e. G., diseases) including, inflammation and/or joint destruction ...
Constant region antibody fusion proteins and compositions thereof
The Scripps Research Institute
July 27, 2017 - N°20170210818

Disclosed herein are antibody fusion constructs and uses thereof. The antibody fusion construct may comprise an antibody fusion protein. The antibody fusion protein may comprise a non-antibody peptide inserted into an antibody portion of the antibody fusion protein. Alternatively, the antibody fusion construct may comprise a bispecific antibody. The bispecific antibody may comprise a second antibody or antibody fragment inserted ...
Disulfur bridge linkers for conjugation of a cell-binding molecule
Suzhou M-conj Biotech Co., Ltd.
July 27, 2017 - N°20170209595

The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of ...
Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
Board Of Regents, The University Of Texas Sytem
July 27, 2017 - N°20170209587

Provided herein are compositions and methods for preparing intraarticular formulations comprising biocompatible pharmaceutical agents and use thereof in the treatment of diseases, such as degenerative bone diseases, including osteoarthritis of the knee, hip, or other joints, and similar chronic or acute destructive arthropathies resulting from autoimmune disorders or infectious disease.
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Disulfur bridge linkers for conjugation of a cell-binding molecule
Suzhou M-conj Biotech Co., Ltd.
July 20, 2017 - N°20170202975

The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of ...
Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone ...
Drk Blutspendedienst Baden-wÜrttemberg-hessen Ggmbh
July 13, 2017 - N°20170198257

The present invention pertains to an improved mesenchymal stromal cell (msc) preparation and a method for producing the same. The invention provides a new strategy to isolate msc from bone marrow mononuclear cells (bm-mncs) by pooling bm-mncs of multiple unrelated (third-party) bone marrow donors. The msc preparation manufactured in accordance with the methodology of the invention is characterized by a ...
Apoptosis signal-regulating kinase inhibitors
Drk Blutspendedienst Baden-wÜrttemberg-hessen Ggmbh
July 13, 2017 - N°20170196844

Wherein x1, x2, x3, x4, x5, x6, x7, x8, r1, r2, r3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or ...
Improved anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
Immco Diagnostics, Inc.
June 22, 2017 - N°20170176454

Provided are compositions that contain mammalian cells for use in detecting antibodies. The mammalian cells are modified such that they do not contain ledgf protein. The mammalian cells are immobilized on a solid substrate. The compositions can also contain mammalian cells that contain the ledgf protein. Methods for using the cell compositions in diagnostic approaches are included, as are kits ...
Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
Southern Research Institute
June 22, 2017 - N°20170174694

The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (lrrk2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal lrrk2 kinase activity. Compounds of the present disclosure can be used to treat disorders including ...
Apoptosis signal-regulating kinase inhibitors
Southern Research Institute
June 22, 2017 - N°20170173031

Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver ...
Cd89 activation in therapy
UniversitÄt Bern
June 15, 2017 - N°20170166640

The invention relates to the use of cd89 activating molecules, in particular fc alpha comprising molecules, and more particularly, iga, for inducing apoptosis in neutrophils. Anti-cd89 antibodies can alternatively be used. The cd89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, netosis, or cystic fibrosis.
Methods and compositions for the generation and maintenance of regulatory t cells
The Brigham And Women's Hospital, Inc.
June 15, 2017 - N°20170165325

Methods and compositions for generating and maintaining induced regulatory t cells (itregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.
Loading